Current Trastuzumab News and Events | Page 2

Current Trastuzumab News and Events, Trastuzumab News Articles.
Sort By: Most Relevant | Most Viewed
Page 2 of 7 | 261 Results
Pertuzumab in early BC: No added benefit proven despite exemplary surrogate validation
The treatment effect on disease-free survival is not large enough to derive an effect on overall survival from it. (2018-10-11)

Mayo Clinic researchers identify a potential new approach to treat HER2 positive breast cancer
Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer. Their findings were published today in Cell Metabolism. (2018-08-30)

Study: Prioritize cardiac monitoring for high-risk breast cancer patients
Overall, heart failure is an uncommon complication of breast cancer treatment; however, the risk is higher in patients treated with certain types of chemotherapy and lower in younger patients, according to a study in a special 'Imaging in Cardio-oncology' issue of JACC: Cardiovascular Imaging. Researchers concluded that cardiac monitoring should be a higher priority for high-risk patients. (2018-08-06)

Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. (2018-07-10)

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects
A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4 percent with 6 months of therapy and 89.8 percent with 12 months of therapy. In addition, only 4 percent of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8 percent in the 12-month arm. (2018-05-16)

New lab study reveals how breast cancer drug can accelerate cancer cell growth
The breast cancer drug lapatinib which is designed to shrink tumors can sometimes cause them to grow in the lab, according to a new study. By understanding the molecular basis of this phenomenon, scientists hope that their findings will lead to safer treatment decision-making and drug design in the future. (2018-05-01)

New drug combo improves survival of women with rare uterine cancer
Adding the monoclonal antibody drug trastuzumab -- already used to treat certain breast cancers -- to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value (2018-04-10)

Fewer breast cancer patients need radical surgery if they are pre-treated with targeted drugs
Extensive surgery involving mastectomy and removal of several lymph nodes can be safely avoided for more women with some types of breast cancer, if they receive targeted drugs before surgery, according to research presented at the 11th European Breast Cancer Conference. (2018-03-22)

Popular heart medications can prevent herceptin-induced heart issues in some patients
Breast cancer patients who started taking one of two well-known heart medications at the same time they initiated trastuzumab -- a targeted cancer therapy that has been linked to heart damage -- received no benefit in terms of preventing declines in heart function, according to research presented at the American College of Cardiology's 67th Annual Scientific Session. (2018-03-11)

Trastuzumab: No negative impact on cardiac function
Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence. (2018-01-03)

Trastuzumab treatment need not delay breast reconstruction following mastectomy
Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy. The first study to assess the effect of trastuzumab on surgical wound complications indicates that breast reconstruction need not be delayed because of the type or length of this form of adjuvant therapy. (2017-10-03)

Scientists discover rogue messengers that hinder body's immune response to cancer
Researchers from Trinity College Dublin have made a discovery around treatment-resistant breast cancer that may turn the phrase, 'don't shoot the messenger', on its head. The scientists have found that cell to cell messengers released by cancer cells which are not responding to treatment, can negatively affect the body's immune system response against the cancer. They have also discovered a possible way for doctors to identify those patients most at risk of treatment resistance. (2017-09-27)

Study finds breast cancer driver, HER2, in 3 percent of lung cancers
The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. (2017-07-27)

Adding a second HER2 blocker may lower chance of invasive breast cancer for some women
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest. (2017-06-05)

Researchers identify biomarkers of response to treatment in invasive breast cancer
Researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy. (2016-12-08)

Brain metastasis persists despite improved targeted treatment for HER2 breast cancer
While new targeted treatments developed across the past two decades have led to dramatic survival improvements for women with HER2-positive metastatic breast cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators report that rates of breast cancer brain metastasis for women with this disease have not substantially declined. (2016-12-07)

Proposed biosimilar drug shows potential as breast cancer treatment
Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA. (2016-12-01)

Costs of similarly effective breast cancer treatments vary widely
A new study finds that the costs of breast cancer chemotherapy vary widely, even among treatment regimens with similar efficacy, and that patients bear a substantial out-of-pocket burden. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study is the first to examine these cost differences, providing clinicians with accessible information to answer patient questions about their treatment options. (2016-10-10)

MD Anderson study finds significant cost differences between breast cancer chemotherapy regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. Understanding cost differences can help guide informed discussions between patients and physicians when considering chemotherapy options. (2016-10-10)

Antibody drug conjugates may help personalize radiotherapy for patients with cancer
Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects. (2016-10-04)

ESC launches novel paper on tackling cardiac toxicity of anticancer therapies
The European Society of Cardiology has launched a novel position paper, under the auspices of its Committee for Practice Guidelines, on tackling the cardiac toxicity of anticancer therapies. The cardio-oncology paper is published online today in European Heart Journal and on the ESC website. (2016-08-27)

New standard helps ensure accurate clinical measurements of HER2 breast cancer gene
Study demonstrates value of new measurement reference for both evaluating assay performance and increasing confidence in reporting HER2 amplification for clinical applications. (2016-08-17)

Researchers restore drug sensitivity in breast cancer tumors
A team of Case Western Reserve University School of Medicine cancer researchers has uncovered one way certain tumors resist vital medication. (2016-08-11)

Anticancer drug discovery: Structures of KDM5 histone demethylase inhibitors
When doctors hurl toxic death at cancer cells, often a few will survive and come back. A family of enzymes called KDM5 histone demethylases is emerging as important for this resilience, and drugs that inhibit KDM5 enzymes could be active in treating several types of cancer. (2016-07-14)

Penn preclinical study outlines cardiovascular side effects of breast cancer drug
A receptor protein that is the target of the breast cancer drug trastuzumab (Herceptin) is needed for proper heart blood-vessel development. These discoveries have implications for better understanding the cardiovascular side effects of trastuzumab commonly used for cancer and provide an example of integration at the molecular level of pathways involved in tissue growth and blood-vessel patterning. (2016-07-13)

MD Anderson study identifies significant cost differences between breast cancer chemotherapy regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. (2016-06-04)

Promising treatment prospects for invasive breast cancer
Scientists from the University of Zurich have been able to understand for the first time why many cancer cells adapt relatively quickly to the treatment with therapeutic antibodies in invasive forms of breast cancer. Instead of dying off, they are merely rendered inactive. The researchers have now developed an active substance that kills the cancer cells very effectively without harming healthy cells. (2016-06-03)

Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age
Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences and the Ted Rogers Centre for Heart Research, University Health Network. (2016-04-19)

Penn Medicine presents evidence showing new drug combination may improve outcomes for women with advanced breast cancer when administered before surgery
Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. Previous studies have shown that a combination of T-DM1 and pertuzumab is safe and effective against advanced, metastatic HER2-positive breast cancer, but in the new results, investigators tested whether the combination would also be effective if given earlier in the course of treatment. (2016-04-18)

Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced frequency of central nervous system metastases, a finding that requires a larger study to confirm, according to an article published online by JAMA Oncology. (2016-04-14)

Older women, especially blacks, receive targeted breast cancer treatment at low rates
The advent of targeted drugs for a specific type of breast cancer -- HER2 positive -- has dramatically improved survival rates for women with the disease. But a study led by researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center reveals low rates of use of a targeted drug among older women with early-stage breast cancer of this type, and even lower rates for older black women. (2016-04-12)

New MD Anderson-developed breast cancer staging system emphasizes importance of tumor biology as prognostic indicator
A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer. (2016-03-17)

Lapatinib and trastuzumab shrinks HER2+ breast cancer in 11 days after diagnosis
Approximately one-quarter of women with HER2 positive breast cancer, who were treated with a combination of two targeted drugs before surgery and chemotherapy, saw their tumors shrink significantly or even disappear, according to results from the UK EPHOS-B clinical trial involving 257 women with newly-diagnosed, operable HER2 positive disease. (2016-03-10)

Single dose of trastuzumab kick starts immune response in certain breast cancers
A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published recently in Clinical Cancer Research. (2016-02-29)

In lung cancer, not all HER2 alterations are created equal
Study shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene. In patient samples of lung adenocarcinoma, 3 percent were found to have HER2 amplification and another 3 percent were found to have HER2 mutation. No samples were found to have both. These distinct causes of HER2 positivity imply the use of different targeted therapies to combat these related but possibly distinct diseases. (2016-01-28)

T-DM1 improved overall survival for heavily pretreated patients with HER2-positive breast cancer
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with trastuzumab emtansine (T-DM1 [Kadcyla]) compared with those who received treatment of physician's choice, according to results from the phase III TH3RESA clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (2015-12-11)

Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit
In contrast to the use in advanced unresectable breast cancer, no positive effects have been proven. However, more patients discontinue treatment, particularly due to cardiac disorders. (2015-12-03)

Antibody-drug compounds and immunotherapy to treat breast cancer
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells. This opens the door to new therapeutic options in the treatment of breast cancer. (2015-11-25)

Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?
EORTC trial 1203 -- Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer, is open for recruitment for patients with early, HER-2 positive gastric cancer. This phase II, randomized EORTC study was developed to investigate the added value of a perioperative treatment regimen which includes HER-2 targeting drugs for patients with gastric and gastro-esophageal junction cancers. (2015-11-13)

ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
Promising clinical trial results presented at the American Society for Clinical Oncology Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients. (2015-05-29)

Page 2 of 7 | 261 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.